Visit for the latest Coronavirus Disease (COVID-19) updates.

You are here

Evidence-Based Resource Summary

Strength of Evidence: 
4 out of 4
4 out of 4
Year Published: 

Fibrates for Secondary Prevention of Cardiovascular Disease and Stroke

Description of Resource: 
Fibrates are a class of drugs that work by positively influencing fats in the blood. This systematic review sought to assess the effect of fibrates for the prevention of major events including heart attacks and strokes in people with existing circulatory disease. This review identified 13 clinical trials and found that when compared primarily to placebo, fibrates can be effective for prevention of major events. However, this beneficial effect relies on the inclusion of data on clofibrates, a drug that was discontinued in 2002 because of safety concerns. There is no good evidence to support the use of currently available fibrates in the prevention of future heart attacks, strokes, and circulatory disease death in people with existing circulatory disease.

Evidence-Based Resource Details

help Learn more about EBR criteria
Developed By: 
Cochrane Review
Developer Type: 
Non-Federal Government
Healthy People 2020 Topic Area(s): 
Heart Disease and Stroke
Healthy People 2020 Objectives: 
Resource Type: 
Systematic Review
Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev [Internet]. 2015 [cited 2017 Dec 29];(10). Art. No.: CD009580. doi: 10.1002/14651858.CD009580.pub2. Available from: